About

Mark Parry has worked with Intertek for over 20 years since graduating from Cambridge University (UK) and currently works as the Senior Scientific Director, supporting the wide range of analytical, formulation, product development and research activities across Intertek . Mr Parry has worked in a range of pharmaceutical analysis and formulation development areas, with a particular focus on inhaled and nasal drug products. Mostly working in the pre-approval stages, Mr Parry’s background includes extensive experience with product and formulation development, as well as method development and validation, stability studies and pharmaceutical development activities for a wide range of clients across the pharmaceutical industry.

Mr Parry is one of DDL’s Scientific Advisors, a member of the EPAG cascade impactor and nasal working groups, and a member of the JPAG organising committee. He routinely presents at conferences, as well as contributing to articles, research papers and posters on a range of respiratory topics.

Contributions

EXPERT VIEW

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.

More contributions

EXPERT VIEW

CONSIDERATIONS WHEN SWITCHING FROM CURRENT pMDI PROPELLANTS TO NEW LOWER-GWP PROPELLANTS

Mark Parry discusses the considerations that need to be made when switching from current pressurised metered dose inhaler propellants to new alternatives with lower global warming potential, including formulation, regulatory and analytical standpoints.

PULMONARY

IN VITRO BIOEQUIVALENCE – WHERE ARE WE NOW?

With a focus on bioequivalence testing in generic inhalables development, Mark Parry highlights shortcomings of aerodynamic particle size distribution and delivered dose testing, and introduces newer testing techniques.